263 related articles for article (PubMed ID: 15914623)
21. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
22. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis.
Agarwal RK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1999 Mar; 162(5):2648-54. PubMed ID: 10072507
[TBL] [Abstract][Full Text] [Related]
24. Suppression of experimental autoimmune uveitis in mice by induction of anterior chamber-associated immune deviation with interphotoreceptor retinoid-binding protein.
Hara Y; Caspi RR; Wiggert B; Chan CC; Wilbanks GA; Streilein JW
J Immunol; 1992 Mar; 148(6):1685-92. PubMed ID: 1531843
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells.
Shao H; Fu Y; Liao T; Peng Y; Chen L; Kaplan HJ; Sun D
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):596-603. PubMed ID: 15671287
[TBL] [Abstract][Full Text] [Related]
26. Effects of experimental ocular inflammation on ocular immune privilege.
Ohta K; Wiggert B; Taylor AW; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2010-8. PubMed ID: 10440255
[TBL] [Abstract][Full Text] [Related]
27. Experimental autoimmune uveitis induced by immunization with retinal pigment epithelium-specific 65-kDa protein peptides.
Nakamura H; Yamaki K; Kondo I; Sakuragi S
Curr Eye Res; 2005 Aug; 30(8):673-80. PubMed ID: 16109648
[TBL] [Abstract][Full Text] [Related]
28. A new procedure for experimental autoimmune uveitis with small uveitogenic peptides.
Sery TW; Su YH; Eagle R; Ueda M; Yamamoto N
Ocul Immunol Inflamm; 2006 Oct; 14(5):277-83. PubMed ID: 17056461
[TBL] [Abstract][Full Text] [Related]
29. [The onset mechanism of experimental autoimmune uveoretinitis induced by interphotoreceptor retinoid-binding protein].
Usui M
Nippon Ganka Gakkai Zasshi; 1992 Dec; 96(12):1580-607. PubMed ID: 1283051
[TBL] [Abstract][Full Text] [Related]
30. S-nitrosoglutathione prevents interphotoreceptor retinoid-binding protein (IRBP(161-180))-induced experimental autoimmune uveitis.
Haq E; Rohrer B; Nath N; Crosson CE; Singh I
J Ocul Pharmacol Ther; 2007 Jun; 23(3):221-31. PubMed ID: 17593005
[TBL] [Abstract][Full Text] [Related]
31. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.
Caspi RR; Chan CC; Grubbs BG; Silver PB; Wiggert B; Parsa CF; Bahmanyar S; Billiau A; Heremans H
J Immunol; 1994 Jan; 152(2):890-9. PubMed ID: 8283058
[TBL] [Abstract][Full Text] [Related]
32. Repertoire analysis and new pathogenic epitopes of IRBP in C57BL/6 (H-2b) and B10.RIII (H-2r) mice.
Cortes LM; Mattapallil MJ; Silver PB; Donoso LA; Liou GI; Zhu W; Chan CC; Caspi RR
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1946-56. PubMed ID: 18436827
[TBL] [Abstract][Full Text] [Related]
33. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.
Kitamei H; Iwabuchi K; Namba K; Yoshida K; Yanagawa Y; Kitaichi N; Kitamura M; Ohno S; Onoé K
J Leukoc Biol; 2006 Jun; 79(6):1193-201. PubMed ID: 16574770
[TBL] [Abstract][Full Text] [Related]
34. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.
Zhang R; He R; Qian J; Guo J; Xue K; Yuan YF
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3575-82. PubMed ID: 20164461
[TBL] [Abstract][Full Text] [Related]
35. Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis.
Silver PB; Tarrant TK; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 May; 40(6):1280-4. PubMed ID: 10235566
[TBL] [Abstract][Full Text] [Related]
36. Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis.
Xu H; Wawrousek EF; Redmond TM; Nickerson JM; Wiggert B; Chan CC; Caspi RR
Eur J Immunol; 2000 Jan; 30(1):272-8. PubMed ID: 10602050
[TBL] [Abstract][Full Text] [Related]
37. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
[TBL] [Abstract][Full Text] [Related]
38. Dissociation between lymphocyte activation for proliferation and for the capacity to adoptively transfer uveoretinitis.
Fox GM; Redmond TM; Wiggert B; Kuwabara T; Chader GJ; Gery I
J Immunol; 1987 May; 138(10):3242-6. PubMed ID: 3106477
[TBL] [Abstract][Full Text] [Related]
39. Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in mice.
Keino H; Takeuchi M; Kezuka T; Yamakawa N; Tsukahara R; Usui M
Graefes Arch Clin Exp Ophthalmol; 2003 Feb; 241(2):111-5. PubMed ID: 12605265
[TBL] [Abstract][Full Text] [Related]
40. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
